RJA
HCAT icon

Raymond James & Associates’s Health Catalyst HCAT Stock Holding History

Raymond James & Associates’s Portfolio HCAT Stock Details HCAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-20,659
Closed -$200K – 3980
2022
Q3 		$200K Sell
20,659
-7,228
-26% -$95.7K ﹤0.01% 3443
2022
Q2 		$404K Sell
27,887
-1,283
-4% -$21.9K ﹤0.01% 3042
2022
Q1 		$762K Sell
29,170
-70,469
-71% -$2M ﹤0.01% 2780
2021
Q4 		$3.95M Sell
99,639
-19,363
-16% -$882K ﹤0.01% 1706
2021
Q3 		$5.95M Buy
119,002
+8,387
+8% +$457K 0.01% 1386
2021
Q2 		$6.14M Buy
110,615
+4,173
+4% +$222K 0.01% 1353
2021
Q1 		$4.98M Buy
106,442
+9,395
+10% +$455K 0.01% 1428
2020
Q4 		$4.22M Sell
97,047
-1,190
-1% -$43.9K ﹤0.01% 1437
2020
Q3 		$3.6M Buy
98,237
+32,987
+51% +$1.12M ﹤0.01% 1403
2020
Q2 		$1.9M Buy
65,250
+53,420
+452% +$1.48M ﹤0.01% 1763
2020
Q1 		$309K Buy
+11,830
New +$361K ﹤0.01% 2744

Other funds holding HCAT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
DG
Daventry Group New York $133M AUM 32.28% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Raymond James & Associates's HCAT Position: Q4 2022 in Review

Raymond James & Associates sold out of Health Catalyst (HCAT) in Q4 2022, closing a stake of 20,659 shares — an estimated $200K sold.

Raymond James & Associates first reported a position in HCAT in Q1 2020 and held it in 11 quarters. The position peaked at $6.14M in Q2 2021. 166 funds tracked by Wall St. Rank hold HCAT as of Q4 2022.

  • Raymond James & Associates reported no remaining Health Catalyst position as of Q4 2022 after selling out during the quarter.
  • Raymond James & Associates sold 20,659 Health Catalyst shares in Q4 2022, an estimated $200K.
  • Raymond James & Associates first reported a position in Health Catalyst in Q1 2020 and held it in 11 quarters.
  • Raymond James & Associates's Health Catalyst position peaked at $6.14M in Q2 2021.
  • 166 funds tracked by Wall St. Rank held Health Catalyst as of Q4 2022.

Based on Raymond James & Associates's 13F filing for Q4 2022, filed 8 Feb 2023.